FLUTICASONE FUROATE AND VILANTEROL- fluticasone furoate and vilanterol trifenatate powder
Fluticasone Furoate/Vilanterol ELLIPTA 100/25 mcg is indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Fluticasone Furoate/Vilanterol ELLIPTA 100/25 mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. Fluticasone Furoate/Vilanterol ELLIPTA 100/25 mcg once daily is the only strength indicated for the treatment of COPD.
Important Limitation of Use
Fluticasone Furoate/Vilanterol ELLIPTA is NOT indicated for the relief of acute bronchospasm
Fluticasone Furoate/Vilanterol ELLIPTA is indicated for the once-daily treatment of asthma in patients aged 18 years and older. Fluticasone Furoate/Vilanterol ELLIPTA should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta2 -adrenergic agonist (LABA).
Important Limitation of Use
Fluticasone Furoate/Vilanterol ELLIPTA is NOT indicated for the relief of acute bronchospasm.
Fluticasone Furoate/Vilanterol ELLIPTA should be administered as 1 inhalation once daily by the orally inhaled route only.
Fluticasone Furoate/Vilanterol ELLIPTA should be used at the same time every day. Do not use Fluticasone Furoate/Vilanterol ELLIPTA more than 1 time every 24 hours.
After inhalation, the patient should rinse his/her mouth with water without swallowing to help reduce the risk of oropharyngeal candidiasis.
More frequent administration or a greater number of inhalations (more than 1 inhalation daily) of the prescribed strength of Fluticasone Furoate/Vilanterol ELLIPTA is not recommended as some patients are more likely to experience adverse effects with higher doses. Patients using Fluticasone Furoate/Vilanterol ELLIPTA should not use additional LABA for any reason. [See Warnings and Precautions (5.3, 5.5, 5.8, 5.12).]
Fluticasone Furoate/Vilanterol ELLIPTA 100/25 mcg should be administered as 1 inhalation once daily. The maximum recommended dosage is 1 inhalation of Fluticasone Furoate/Vilanterol ELLIPTA 100/25 mcg once daily, the only strength indicated for the treatment of COPD.
If shortness of breath occurs in the period between doses, an inhaled, short-acting beta2 -agonist (rescue medicine, e.g., albuterol) should be taken for immediate relief.
The recommended starting dosage is Fluticasone Furoate/Vilanterol ELLIPTA 100/25 mcg or Fluticasone Furoate/Vilanterol ELLIPTA 200/25 mcg administered as 1 inhalation once daily.
When choosing the starting dosage strength of Fluticasone Furoate/Vilanterol ELLIPTA, consider the patients’ disease severity, based on their previous asthma therapy, including the ICS dosage, as well as the patients’ current control of asthma symptoms and risk of future exacerbation.
The maximum recommended dosage is 1 inhalation of Fluticasone Furoate/Vilanterol ELLIPTA 200/25 mcg once daily.
The median time to onset, defined as a 100-mL increase from baseline in mean forced expiratory volume in 1 second (FEV1 ), was approximately 15 minutes after beginning treatment. Individual patients will experience a variable time to onset and degree of symptom relief.
For patients who do not respond adequately to Fluticasone Furoate/Vilanterol ELLIPTA 100/25 mcg, increasing the dose to Fluticasone Furoate/Vilanterol ELLIPTA 200/25 mcg may provide additional improvement in asthma control.
If asthma symptoms arise in the period between doses, an inhaled, short-acting beta2 -agonist (rescue medicine, e.g., albuterol) should be taken for immediate relief.
If a previously effective dosage regimen of Fluticasone Furoate/Vilanterol ELLIPTA fails to provide adequate improvement in asthma control, the therapeutic regimen should be reevaluated and additional therapeutic options (e.g., replacing the current strength of Fluticasone Furoate/Vilanterol ELLIPTA with a higher strength, adding additional ICS, initiating oral corticosteroids) should be considered.
Inhalation powder: Disposable light grey and pale blue plastic inhaler containing 2 foil blister strips of powder intended for oral inhalation only. One strip contains fluticasone furoate (100 or 200 mcg per blister), and the other strip contains vilanterol (25 mcg per blister).
The use of Fluticasone Furoate/Vilanterol ELLIPTA is contraindicated in the following conditions:
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required [see Warnings and Precautions (5.2)].
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, vilanterol, or any of the excipients [see Warnings and Precautions (5.11), Description (11)].
Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death [see Salmeterol Multicenter Asthma Research Trial (SMART)]. Available data from controlled clinical trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA monotherapy. When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma‑related events (hospitalizations, intubations, death) compared with ICS alone (see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta2 -adrenergic Agonists).
Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta2 -adrenergic Agonists
Four (4) large, 26-week, randomized, double-blind, active-controlled clinical safety trials were conducted to evaluate the risk of serious asthma-related events when LABA were used in fixed‑dose combination with ICS compared with ICS alone in subjects with asthma. Three (3) trials included adult and adolescent subjects aged 12 years and older: 1 trial compared budesonide/formoterol with budesonide, 1 trial compared fluticasone propionate/salmeterol inhalation powder with fluticasone propionate inhalation powder, and 1 trial compared mometasone furoate/formoterol with mometasone furoate. The fourth trial included pediatric subjects aged 4 to 11 years and compared fluticasone propionate/salmeterol inhalation powder with fluticasone propionate inhalation powder. The primary safety endpoint for all 4 trials was serious asthma-related events (hospitalizations, intubations, death). A blinded adjudication committee determined whether events were asthma related.
The 3 adult and adolescent trials were designed to rule out a risk margin of 2.0, and the pediatric trial was designed to rule out a risk margin of 2.7. Each individual trial met its pre-specified objective and demonstrated non-inferiority of ICS/LABA to ICS alone. A meta-analysis of the 3 adult and adolescent trials did not show a significant increase in risk of a serious asthma-related event with ICS/LABA fixed-dose combination compared with ICS alone (Table 1). These trials were not designed to rule out all risk for serious asthma-related events with ICS/LABA compared with ICS.
|ICS = Inhaled Corticosteroid, LABA = Long-acting Beta2 -adrenergic Agonist.|
|a Randomized subjects who had taken at least 1 dose of study drug. Planned treatment used for analysis.|
|b Estimated using a Cox proportional hazards model for time to first event with baseline hazards stratified by each of the 3 trials.|
|c Number of subjects with event that occurred within 6 months after the first use of study drug or 7 days after the last date of study drug, whichever date was later. Subjects can have one or more events, but only the first event was counted for analysis. A single, blinded, independent adjudication committee determined whether events were asthma related.|
(n = 17,537)a
(n = 17,552)a
ICS/LABA vs. ICS
Hazard Ratio (95% CI)b
Serious asthma-related eventc
1.10 (0.85, 1.44)
The pediatric safety trial included 6,208 pediatric subjects aged 4 to 11 years who received ICS/LABA (fluticasone propionate/salmeterol inhalation powder) or ICS (fluticasone propionate inhalation powder). In this trial, 27/3,107 (0.9%) subjects randomized to ICS/LABA and 21/3,101 (0.7%) subjects randomized to ICS experienced a serious asthma-related event. There were no asthma-related deaths or intubations. ICS/LABA did not show a significantly increased risk of a serious asthma-related event compared with ICS based on the pre-specified risk margin (2.7), with an estimated hazard ratio of time to first event of 1.29 (95% CI: 0.73, 2.27).
Salmeterol Multicenter Asthma Research Trial (SMART)
A 28-week, placebo-controlled, U.S. trial that compared the safety of salmeterol with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in subjects receiving salmeterol (13/13,176 in subjects treated with salmeterol versus 3/13,179 in subjects treated with placebo; relative risk: 4.37 [95% CI: 1.25, 15.34]). Use of background ICS was not required in SMART. The increased risk of asthma-related death is considered a class effect of LABA monotherapy.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.